KRAS and breast cancer: For this reason, we evaluated if these compounds were also capable of stabilizing the complex formed by the exclusive mutant form of K-Ras4B reported in breast cancer K-Ras4BG13D and this membrane transporter PDE6δ (K-Ras4BG13D/PDE6δ) to inhibit its oncogenic activity.